Clinical trial
A Phase 2a, Double-blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of IRL201104 in Adult Participants With Active Eosinophilic Esophagitis (EoE)
NCT05084963 is registered in ClinicalTrials.gov with Revolo Biotherapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Double-blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of IRL201104 in Adult Participants With Active Eosinophilic Esophagitis (EoE)
- Lead sponsor
- Revolo Biotherapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 29, 2021
- Completion date
- October 24, 2022
- Enrollment
- 36 (actual)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.